LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Key Highlights
- ➤Q3 2026 financial results scheduled for October 29, 2026
- ➤Webcast begins October 29 at 8:30 a.m. EDT
- ➤VIZZ is FDA-approved for adult presbyopia treatment
- ➤LENZ continues establishing international VIZZ licensing partnerships
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ(®) (link) (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.
To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
Get started
Create a free account to read the full story.